Cargando…

Biofilm Formation of Clostridioides difficile, Toxin Production and Alternatives to Conventional Antibiotics in the Treatment of CDI

Clostridioides difficile is considered a nosocomial pathogen that flares up in patients exposed to antibiotic treatment. However, four out of ten patients diagnosed with C. difficile infection (CDI) acquired the infection from non-hospitalized individuals, many of whom have not been treated with ant...

Descripción completa

Detalles Bibliográficos
Autor principal:	Dicks, Leon M. T.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10534356/ https://www.ncbi.nlm.nih.gov/pubmed/37764005 http://dx.doi.org/10.3390/microorganisms11092161

Ejemplares similares

Investigational Treatment Agents for Recurrent Clostridioides difficile Infection (rCDI)
por: Kullar, Ravina, et al.
Publicado: (2020)

Clostridioides difficile infection (CDI) during the COVID-19 pandemic
por: Spigaglia, Patrizia
Publicado: (2022)

135. Impact of Clostridioides difficile Toxin Confirmation on Subsequent C. difficile Treatment in a Rural Health System (IT-CDI)
por: Crawford, Jacquelyn, et al.
Publicado: (2023)

Incidence of Clostridioides difficile infection (CDI) related to antibiotic prescribing by GP surgeries in Wales
por: Tydeman, Florence, et al.
Publicado: (2021)

Antibiotic Resistance and Biofilm Production Capacity in Clostridioides difficile
por: Rahmoun, Layan Abu, et al.
Publicado: (2021)

Burden of Clostridioides difficile infection (CDI) - a systematic review of the epidemiology of primary and recurrent CDI
por: Finn, Elaine, et al.
Publicado: (2021)

2385. Evaluating the Antibiotic Risk for Clostridioides difficile Infection (CDI): Comparing Piperacillin/Tazobactam to Cefepime and Ceftazidime
por: Rathod, Shardul, et al.
Publicado: (2019)

684. Characteristics of Patients with Initial Clostridioides difficile Infection (CDI) That Are Associated With Increased Risk of Multiple CDI Recurrences
por: Guh, Alice, et al.
Publicado: (2023)

Clostridioides difficile infection (CDI) treatment outcomes and recurrence factor at a pediatric hospital
por: Tran, Martin Tuan, et al.
Publicado: (2022)

Review of the Impact of Biofilm Formation on Recurrent Clostridioides difficile Infection
por: Rubio-Mendoza, Daira, et al.
Publicado: (2023)

2’-Fucosyllactose inhibits proliferation of Clostridioides difficile ATCC 43599 in the CDi-screen, an in vitro model simulating Clostridioides difficile infection
por: Wiese, Maria, et al.
Publicado: (2022)

Frontiers in antibiotic alternatives for Clostridioides difficile infection
por: Phanchana, Matthew, et al.
Publicado: (2021)

COVID-19 and Clostridioides difficile infection (CDI): Possible implications for elderly patients
por: Spigaglia, Patrizia
Publicado: (2020)

An Update on Clostridioides difficile Binary Toxin
por: Martínez-Meléndez, Adrián, et al.
Publicado: (2022)

SER-109: An Oral Investigational Microbiome Therapeutic for Patients with Recurrent Clostridioides difficile Infection (rCDI)
por: Khanna, Sahil, et al.
Publicado: (2022)

Spore Formation and Toxin Production in Clostridium difficile Biofilms
por: Semenyuk, Ekaterina G., et al.
Publicado: (2014)

1211. Response to Fecal Microbiota Transplant (FMT) in Refractory Clostridioides difficile Infection (CDI) is Modest Compared to Recurrent CDI in Hospitalized Patients
por: Shin, Jae Hyun, et al.
Publicado: (2020)

A point-prevalence study on community and inpatient Clostridioides difficile infections (CDI): results from Combatting Bacterial Resistance in Europe CDI (COMBACTE-CDI), July to November 2018
por: Viprey, Virginie F, et al.
Publicado: (2022)

New advances in the treatment of Clostridium difficile infection (CDI)
por: Hedge, Dennis D, et al.
Publicado: (2008)

Initial therapy affects duration of diarrhoea in critically ill patients with Clostridioides difficile infection (CDI)
por: Manthey, Carolin F., et al.
Publicado: (2019)

Extraintestinal Clostridioides difficile Infection (CDI): A Recurrent Battle with Resilient Abdominal Wall Abscess
por: Chinnappan, Justine, et al.
Publicado: (2023)

785. Association between Prevalence of Laboratory-Identified Clostridioides difficile Infections (CDIs) and CDI Antibiotic Treatment in U.S. Acute Care Hospitals, 2018
por: Xu, Kerui, et al.
Publicado: (2020)

The prognostic value of toxin B and binary toxin in Clostridioides difficile infection
por: López-Cárdenas, Salvador, et al.
Publicado: (2021)

Fidaxomicin Preserves the Intestinal Microbiome During and After Treatment of Clostridium difficile Infection (CDI) and Reduces Both Toxin Reexpression and Recurrence of CDI
por: Louie, Thomas J., et al.
Publicado: (2012)

Impact of deoxycholate on Clostridioides difficile growth, toxin production, and sporulation
por: Usui, Yukino, et al.
Publicado: (2020)

Iron Effects on Clostridioides difficile Toxin Production and Antimicrobial Susceptibilities
por: Yamaki, Jason, et al.
Publicado: (2022)

Extracellular succinate induces spatially organized biofilm formation in Clostridioides difficile
por: Auria, Emile, et al.
Publicado: (2023)

2382. Recurrent Clostridioides difficile Infection (CDI) Worsens Anxiety-Related Patient-Reported Quality of Life
por: Garey, Kevin W, et al.
Publicado: (2019)

710. Burden of Clostridioides difficile Infection (CDI) in Flint, Michigan (MI): Association of Race and Gender with Mortality
por: Younas, Mariam, et al.
Publicado: (2023)

The Importance of Therapeutically Targeting the Binary Toxin from Clostridioides difficile
por: Abeyawardhane, Dinendra L., et al.
Publicado: (2021)

704. Antibiotic Use Audit in Hospital-onset Clostridioides difficile (HO-CDI) Cases in a Tertiary Medical Center in New York City
por: Swaminathan, Neeraja, et al.
Publicado: (2023)

Biofilm regulation in Clostridioides difficile: Novel systems linked to hypervirulence
por: Taggart, Megan G., et al.
Publicado: (2021)

1930. Quality of Life among Patients with Community-onset Clostridioides difficile Infection (CDI) without Subsequent Hospitalization
por: Schmidt, Mark A, et al.
Publicado: (2023)

The Alternative Sigma Factor SigL Influences Clostridioides difficile Toxin Production, Sporulation, and Cell Surface Properties
por: Clark, Andrew E., et al.
Publicado: (2022)

Clostridioides difficile spore: coat assembly and formation
por: Zeng, Ji, et al.
Publicado: (2022)

973 Use of Concomitant Antibiotics During Treatment for Clostridium difficile Infection (CDI) in Pediatric Inpatients
por: Stevens, Vanessa, et al.
Publicado: (2014)

394. Impact of Misdiagnosis of Clostridioides difficile Infection (CDI) by Standard-of-care Specimen Collection and Testing on Estimates of Hospitalized CDI Incidence Among Adults in Louisville, Kentucky, 2019-2020
por: Ramirez, Julio A, et al.
Publicado: (2022)

Influence of L-lactate and low glucose concentrations on the metabolism and the toxin formation of Clostridioides difficile
por: Hofmann, Julia Danielle, et al.
Publicado: (2021)

741. Antifungal Resistant Candida glabrata Are Most Commonly Colonized in Clostridioides difficile Infection (CDI) Patient Guts in Texas
por: Begum, Khurshida, et al.
Publicado: (2020)

Fecal Microbiota Transplant in Severe and Non-Severe Clostridioides difficile Infection. Is There a Role of FMT in Primary Severe CDI?
por: Popa, Daniel, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_gffo8ncsf55p6scgu1tsbkfs50